Suzuki Motorcycle India Pvt. Ltd. (SMIPL) registers a 5.4% Y-O-Y growth in February 2021. The brand recorded total sales of 71,662 units in the month of February 2021 compared to 67,961 units sold in February 2020. In the domestic market, Suzuki registered sales of 59,530 units in February 2021 as compared to 58,644 units sold in February 2020, despite the COVID-19 pandemic. The brand also suggests that the sales are slowly riding towards pre-COVID levels and the brand expects the sales to improve more in the near future.
Suzuki retails five motorcycles in the Indian market – the Gixxer SF 250, Gixxer 250, Gixxer SF (150), Gixxer (150) and the Intruder (150). The brand also offers two scooters – the Burgman 125 Street and the Access 125 in India. Suzuki also retails superbikes from its ‘Big Bike’ portfolio which currently has only one motorcycle on offer which is the BS6 Suzuki V-Strom 650 XT. But the brand recently confirmed that it will also bring the all-new third-generation Suzuki Hayabusa into the Indian market soon.
Suzuki released a teaser of the all-new Hayabusa confirming that the iconic motorcycle will be ‘Coming Soon to India’. The all-new model recently made its debut in the international market and comes with a new body design, mild upgrades to its chassis, the same engine architecture but new innards such as the pistons, camshafts, valve springs, connecting rods, combustion chamber, intake system, throttle body, fuel injection system as well as the exhaust system. The gentle giant has also managed to shed 2 kgs of weight in the engine department and another 700gms off its chassis.
Hayabusa Powertrain Specifications
Powering the 2021 Suzuki Hayabusa is a Euro5 emission compliant 1340cc liquid-cooled in-line four-cylinder 16-valve DOHC engine with electronic fuel injection that produces 187 bhp of power at 9700rpm and 150 Nm of torque at 7000rpm. The engine comes with a 6-speed transmission unit with a bi-directional quick shifter. As of now, the brand has not revealed which route the Hayabusa will take to enter the Indian market, will it be the more expensive CBU route or the relatively affordable CKD route, remains to be seen.